Quality of life as a prognostic marker in pulmonary arterial hypertension

Health and Quality of Life Outcomes

Rogério Souza²  Susana Hoette²  Ana Paula Breda²  Luciana K Morinaga²  Rozana M Ciconelli¹  Carlos VP Jardim²  Barbara CS Martins²  Caio JCS Fernandes² 

[1] Rheumatology Department, Federal University of Sao Paulo, Sao Paulo, Brazil;Pulmonary Department, Heart Institute ¿ University of Sao Paulo Medical School, Medical School. Av. Dr. Eneas de Carvalho Aguiar, 44, Sao Paulo, 05403-000, Brazil

关键词: Treatment;    Prognosis;    Survival;    Pulmonary arterial hypertension;    Quality of life;   

Others  :  1164532
DOI  :  10.1186/s12955-014-0130-3

 received in 2014-03-25, accepted in 2014-08-08,  发布年份 2014

【 摘 要 】

Background

Improvement in quality of life together with better survival are the ultimate goals in the treatment of pulmonary arterial hypertension (PAH) patients. The objective of this study was to evaluate the health-related quality of life (HRQL) of pulmonary arterial hypertension (PAH) patients with the SF-36 generic questionnaire and to identify the prognostic implication of this assessment.

Methods

Fifty-four consecutive newly diagnosed PAH patients (WHO classification group I) in a single PAH reference center were included. Patients were evaluated at baseline for clinical and hemodynamic parameters, and they subsequently received first-line therapy with either an endothelin receptor antagonist or a phosphodiesterase-5 inhibitor. After 16 weeks of specific PAH therapy, all patients were re-evaluated using a 6MWT and a SF 36 questionnaire, and then they were followed up for at least 36 months.

Results

After treatment, the patients demonstrated an improved 6MWT (414?±?124 m vs. 440?±?113 m, p?=?0.001). Specific PAH therapy also improved the HRQL scores.

Patients with a baseline Physical Component Score (PCS) higher than 32 had a better survival rate than those who had a score under 32 (p?=?0.04). Similarly, patients with a PCS of at least a 38 after the 16 week therapy period had a better survival rate when compared with those who did not achieve this value (p?=?0.016). Unlike the absolute PCS values, the post-treatment PCS variability was unable to predict better survival rates (p?=?0.58).

Conclusions

Our findings suggest that HRQL is associated with prognosis in PAH. Furthermore, achieving pre-determined PCS scores might represent a specific goal to be reached in treatment-to-target strategies.

【 授权许可】

   
2014 Fernandes et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Souza R, Jardim C, Humbert M: Idiopathic pulmonary arterial hypertension. Semin Respir Crit Care Med 2013, 34:560-567.
• [2]McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M: Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013, 62:D51-D59.
• [3]Hoette S, Jardim C, Souza R: Diagnosis and treatment of pulmonary hypertension: an update. J Bras Pneumol 2010, 36:795-811.
• [4]Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800-804.
• [5]Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, Landzberg M, Simonneau G: Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002, 346:896-903.
• [6]Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
• [7]Fijalkowska A, Kurzyna M, Torbicki A, Szewczyk G, Florczyk M, Pruszczyk P, Szturmowicz M: Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. Chest 2006, 129:1313-1321.
• [8]Souza R, Jardim C, Carvalho C, Rubenfeld G: The role of NT-proBNP as a prognostic marker in pulmonary hypertension. Chest 2006, 130:1627. author reply 1627-8
• [9]Souza R, Jardim C, Julio Cesar Fernandes C, Silveira Lapa M, Rabelo R, Humbert M: NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension. Respir Med 2007, 101:69-75.
• [10]Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A: A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009, 30:394-403.
• [11]Shafazand S, Goldstein MK, Doyle RL, Hlatky MA, Gould MK: Health-related quality of life in patients with pulmonary arterial hypertension. Chest 2004, 126:1452-1459.
• [12]Bonner N, Abetz L, Meunier J, Sikirica M, Mathai SC: Development and validation of the living with pulmonary hypertension questionnaire in pulmonary arterial hypertension patients. Health Qual Life Outcomes 2013, 11:161. BioMed Central Full Text
• [13]McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J: The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): a measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006, 15:103-115.
• [14]McHorney CA, Ware JE Jr, Lu JF, Sherbourne CD, The MOS: 36-item Short-Form Health Survey (SF-36): III: tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994, 32:40-66.
• [15]Brazier JE, Harper R, Jones NM, O¿Cathain A, Thomas KJ, Usherwood T, Westlake L: Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992, 305:160-164.
• [16]Keogh AM, McNeil KD, Wlodarczyk J, Gabbay E, Williams TJ: Quality of life in pulmonary arterial hypertension: improvement and maintenance with bosentan. J Heart Lung Transplant 2007, 26:181-187.
• [17]Pepke-Zaba J, Beardsworth A, Chan M, Angalakuditi M: Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension. Curr Med Res Opin 2009, 25:2479-2485.
• [18]Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB: Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149:521-530.
• [19]Souza R, Jardim C, Martins B, Cortopassi F, Yaksic M, Rabelo R, Bogossian H: Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension. Curr Med Res Opin 2005, 21:907-911.
• [20]Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghofrani A, Gomez Sanchez MA, Krishna Kumar R, Landzberg M, Machado RF, Olschewski H, Robbins IM, Souza R: Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013, 62:D34-D41.
• [21]ATS statement: guidelines for the six-minute walk test.Am J Respir Crit Care Med 2002, 166:111¿117.
• [22]Costa EL, Jardim C, Bogossian HB, Amato MB, Carvalho CR, Souza R: Acute vasodilator test in pulmonary arterial hypertension: evaluation of two response criteria. Vascul Pharmacol 2005, 43:143-147.
• [23]Ciconelli R, Ferraz MB, Santos W, Quaresma M: Tradução para a Língua Portuguesa e validação do questionário genérico da avaliação de qualidade de vida SF-36 (Brasil SF-36). Rev Bras Reumatol 1999, 39:8.
• [24]Fernandes CJ, Jardim CV, Hovnanian A, Hoette S, Morinaga LK, Souza R: Schistosomiasis and pulmonary hypertension. Expert Rev Respir Med 2011, 5:675-681.
• [25]Hovnanian A, Hoette S, Fernandes CJ, Jardim C, Souza R: Schistosomiasis associated pulmonary hypertension.Int J Clin Pract Suppl 2010, ? 25¿28.
• [26]Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD: An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest 2012, 142:448-456.
• [27]Souza R, Martins BC, Jardim C, Cortopassi F, Fernandes CJ, Pulido T, Sandoval J: Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension. Int J Clin Pract 2007, 61:153-156.
• [28]Galie N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, Badesch DB, McGoon MD, McLaughlin VV, Roecker EB, Gerber MJ, Dufton C, Wiens BL, Rubin LJ: Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117:3010-3019.
• [29]Rival G, Lacasse Y, Martin S, Bonnet S, Provencher S: Effect of pulmonary arterial hypertension specific therapies on health-related quality of life: a systematic review.Chest 2014.
• [30]Roman A, Barbera JA, Castillo MJ, Munoz R, Escribano P: Health-related quality of life in a national cohort of patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension. Arch Bronconeumol 2013, 49:181-188.
• [31]Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G: Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002, 40:780-788.
• [32]Hoeper MM, Markevych I, Spiekerkoetter E, Welte T, Niedermeyer J: Goal-oriented treatment and combination therapy for pulmonary arterial hypertension. Eur Respir J 2005, 26:858-863.
• [33]Gabler NB, French B, Strom BL, Palevsky HI, Taichman DB, Kawut SM, Halpern SD: Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012, 126:349-356.
• [34]Gilbert C, Brown MC, Cappelleri JC, Carlsson M, McKenna SP: Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil. Chest 2009, 135:137-142.
• [35]Cima K, Twiss J, Speich R, McKenna SP, Grunig E, Kahler CM, Ehlken N, Treder U, Crawford SR, Huber LC, Ulrich S: The German adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). Health Qual Life Outcomes 2012, 10:110. BioMed Central Full Text
• [36]Coffin D, Duval K, Martel S, Granton J, Lefebvre MC, Meads DM, Twiss J, McKenna SP: Adaptation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) into French-Canadian and English-Canadian. Can Respir J 2008, 15:77-83.
• [37]Selimovic N, Rundqvist B, Kjork E, Viriden J, Twiss J, McKenna SP: Adaptation and validation of the Cambridge pulmonary hypertension outcome review for Sweden. Scand J Public Health 2012, 40:777-783.
• [38]Gomberg-Maitland M, Thenappan T, Rizvi K, Chandra S, Meads DM, McKenna SP: United States validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR). J Heart Lung Transplant 2008, 27:124-130.
• [39]Ganderton L, Jenkins S, McKenna SP, Gain K, Fowler R, Twiss J, Gabbay E: Validation of the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for the Australian and New Zealand population. Respirology 2011, 16:1235-1240.
• [40]McCabe C, Bennett M, Doughty N, MacKenzie Ross R, Sharples L, Pepke-Zaba J: Patient-reported outcomes assessed by the CAMPHOR questionnaire predict clinical deterioration in idiopathic pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Chest 2013, 144:522-530.
• [41]Dos Santos Fernandes CJ, Jardim CV, Hovnanian A, Hoette S, Dias BA, Souza S, Humbert M, Souza R: Survival in schistosomiasis-associated pulmonary arterial hypertension. J Am Coll Cardiol 2010, 56:715-720.
• [42]Fernandes CJ, Dias BA, Jardim CV, Hovnanian A, Hoette S, Morinaga LK, Souza S, Suesada M, Breda AP, Souza R: The role of target therapies in schistosomiasis-associated pulmonary arterial hypertension. Chest 2012, 141:923-928.
• [43]Lapa M, Dias B, Jardim C, Fernandes CJ, Dourado PM, Figueiredo M, Farias A, Tsutsui J, Terra-Filho M, Humbert M, Souza R: Cardiopulmonary manifestations of hepatosplenic schistosomiasis. Circulation 2009, 119:1518-1523.